Insider · CIK 0001496194
J. Christopher Naftzger
Files at ABUS (Arbutus Biopharma Corp). First filing Feb 5, 2025, latest Feb 5, 2025.
J. Christopher Naftzger files SEC Form 4 as officer at ABUS (Arbutus Biopharma Corp). Since Feb 5, 2025, J. Christopher Naftzger has reported 0 open-market buys worth $0 and 1 open-market sell worth $37k, the latest filed on Feb 5, 2025.
A track record needs three past buys with six months of prices behind them; J. Christopher Naftzger has 0, so none is measured yet.
The newest scored trade: sold $37k of ABUS on Feb 4, 2025, filed Feb 5, 2025, scored 21 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ABUS: Arbutus Biopharma Corp
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Arbutus Biopharma Corp | $37k 11,333 shares | -12% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 4, 2025 | ABUS Arbutus Biopharma Corporation | 11,333 13.14% of outstanding | $37k | Feb 4, 2025 | none |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | ABUS Arbutus Biopharma Corp | AGrant or award Common Shares | +54,300 | $0.00 | $0 | 140,544 | Feb 19, 2025 |
| Feb 14, 2025 | ABUS Arbutus Biopharma Corp | AGrant or award Stock Option (Right to Buy)derivative | +220,300 | $0.00 | $0 | 220,300 | Feb 19, 2025 |
| Feb 4, 2025 | ABUS Arbutus Biopharma Corp | SOpen-market sale Common Shares10b5-1 | -11,333 | $3.28 | $37k | 86,244 | Feb 5, 2025 |
Questions about J. Christopher Naftzger
Answered from the filings on this page, as of the latest one.
Is J. Christopher Naftzger buying or selling?
Not in the last 12 months. J. Christopher Naftzger's latest open-market trade on SEC Form 4 was sold $37k of ABUS on Feb 4, 2025.
How did J. Christopher Naftzger's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and J. Christopher Naftzger has 0.
Where does J. Christopher Naftzger file Form 4?
J. Christopher Naftzger has filed Form 4 at ABUS (Arbutus Biopharma Corp) as General Counsel and CCO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.